STAT+: Moderna’s suing Pfizer? Wow! OK, now take a deep breath.
It’s the stuff that headline writers’ dreams are made of: Moderna is suing Pfizer and…
Category: biotechnology
Moderna sues Pfizer and BioNTech over Covid-19 vaccine
Moderna on Friday sued Pfizer and BioNTech, its main rivals in the mRNA Covid vaccine…
STAT+: How a long-overlooked protein could remake neuroscience drug discovery — or plunge the FDA into controversy
So, imagine you get punched in the head. Not once, but a bunch of times….
STAT+: Faster drug approval route sparks investment in rare kidney disease treatments
Recent years have seen a surge of research into rarer forms of kidney disease, with…
.jpg)
STAT+: OrbiMed tumbles from the top of STAT’s biotech venture capital performance ranking
Noted biotech investment firm OrbiMed slid from first place to 14th in STAT’s latest annual…
When spinal fluid from ALS patients was put into mice, the mice got weak. An unlikely protein could be the culprit
It was a shot in the dark — or at best, a dimly lit room:…
STAT+: FDA approves Axsome’s fast-acting treatment for major depression
After a lengthy review, the Food and Drug Administration approved a fast-acting depression treatment from…
Listen: Private equity in autism care, a watershed FDA approval, and the future of ALS treatment
How did autism care become a big business? Can gene therapy be profitable? And whatever…
STAT+: ‘We’re finally here’: Harvard graduate spearheads custom gene therapy for younger brother
Richard Horgan has waited for this moment for more than three years. Last month, the…
STAT+: Bluebird wins U.S. approval for a gene therapy to treat patients with a rare blood disorder
The Food and Drug Administration on Wednesday approved a new treatment that delivers a potentially…
STAT+: Ex-Google CEO’s VC firm brings in hype-busting researcher to expand its biotech investments
Innovation Endeavors, the venture capital firm co-founded by former Google chairman and CEO Eric Schmidt,…
STAT+: Frustrated with nature’s biomarkers for cancer, biologists try making their own
On Target is a recurring feature from STAT that dives deep into the most promising…
STAT+: Merck, a loser in the Covid vaccine race, reinvests in mRNA through a Cambridge startup
Among the most notable aspects of the Covid-19 vaccine race was who won it: Pfizer…
STAT+: Brainstorm to seek FDA approval for ALS stem-cell treatment, despite agency objections
Last year, the Food and Drug Administration issued a rare public statement to inform the…
Listen: Big egos in Big Science, the return of Merger Monday, & the fallout over drug pricing
Are biotech’s fortunes finally changing? Is Big Science impeding actual science? And what will Medicare…
STAT+: Amid Aduhelm woes, Biogen moves to pare back office space
Biogen is moving to scale back its real estate footprint in Kendall Square and in Weston,…
STAT+: Everything you need to know before the next big Alzheimer’s readout
With the tumultuous rollout of Aduhelm behind them, partners Biogen and Eisai have the rare…
STAT+: With Pfizer deal, Global Blood CEO sees opportunity to reach sickle cell patients globally
The $5.4 billion acquisition of Global Blood Therapeutics by Pfizer was sealed with a phone…
STAT+: Karuna Therapeutics’ schizophrenia drug achieves study goals, heralding new treatment approach
Karuna Therapeutics said Monday that a novel combination pill reduced psychosis and related symptoms experienced…
STAT+: Serious liver side effects detour Amgen’s effort to expand use of its KRAS-blocking lung cancer drug
A clinical trial run by Amgen that combined its KRAS-targeting cancer drug called Lumakras with…
Listen: The last-minute push for drug pricing reform, Alnylam’s success, and Sarepta’s gamble
Is drug pricing reform really happening this time? Are things finally turning around for biotech?…
STAT+: Amgen to acquire ChemoCentryx for $4 billion, adding newly approved drug for autoimmune disorder
Amgen said Thursday that it will acquire the small drugmaker ChemoCentryx for $4 billion to…
STAT+: Alnylam therapy for increasingly common heart disease succeeds in closely watched trial
Alnylam Pharmaceuticals’ treatment for an increasingly common heart disease succeeded in a closely watched clinical…
STAT+: Alexis Borisy, biotech’s ‘man of many hats,’ dons another
Alexis Borisy is the first person to admit he has a lot of projects going…
STAT+: Sarepta to seek early FDA approval for gene therapy to treat Duchenne muscular dystrophy
Sarepta Therapeutics said Friday that it intends seek regulators’ approval for its gene therapy to…
Drug companies could create new drugs to protect the Covid vulnerable. Why aren’t they?
Twice, Janet Handal thought she would get a reprieve from semi-lockdown life. The first was…
STAT+: FDA agrees to review ALS treatment from Biogen, despite inconclusive clinical trial results
The Food and Drug Administration has agreed to review a treatment for a rare, genetically…
STAT+: American Cancer Society’s VC arm partners with Third Rock on oncology companies
Cancer startups aren’t exactly underfunded — as a disease area, oncology has commanded investors’ attention…
As new variant spreads, a crucial drug to protect the most vulnerable goes vastly underused
Jennifer Padgett has spent 2 1/2 years terrified for her immunocompromised daughter, Hannah. Hannah catches…
Listen: Well-paid CEOs, behind the scenes at Moderna, & Biogen’s CEO search
Does any CEO deserve $500 million a year? How did Moderna hit it big? And…
STAT+: This biotech is betting dietary changes can reshape cancer care. Even if it works, can Faeth make a profit?
For all the advances oncology researchers have made in genomics and precision medicine, one of…
A CEO pay bonanza, how much the rank and file are paid, and a wilderness therapy rabbit hole
You’re reading the web edition of Health Care Inc., STAT’s weekly newsletter following the flow…
STAT+: New data might have led to a different result for Amarin fish oil drug, FDA panelists say
Two members of an expert panel that recommended the Food and Drug Administration approve a…
STAT+: Biotech executives pull in some of health care’s biggest paydays, with Regeneron’s CEO sitting atop the pack
When it comes to executive compensation in the biotech and pharma sectors, it pays to…
Biotech employees cash in health care’s largest salaries, while people working at providers sit near the bottom
It pays to be in the lab. It pays way less to be at the…
Health care’s high rollers: As the pandemic raged, CEOs’ earnings surged
Health care’s top executives sat comfortably atop their perch during the second year of the…
STAT+: George Church startup Manifold Bio raises $40M for ‘protein barcoding’ technology to improve drug testing
Manifold Bio, a new startup founded by one of Boston’s most prolific biotech entrepreneurs, has…
STAT+: Agios Pharma CEO Jackie Fouse to step down, as a former Alexion executive takes over
Jackie Fouse is stepping down as CEO of Agios Pharmaceuticals, replaced by Brian Goff, a…
STAT+: Verve Therapeutics begins human tests of first ‘base editor,’ aiming at heart disease
Somewhere in New Zealand, the first patient ever has been dosed with a kind of…
Opinion: STAT+: How pharma and biotech can keep innovating in a bear market
Over the last decade, the biotech sector experienced the largest boom it has ever seen….
Listen: VC malaise, FDA confusion, & yet another Alzheimer’s debate
Is the era of the unicorn over? What’s gotten into the FDA? And will a…
STAT+: With ‘do-over’ NASH results, Intercept will seek approval for first-ever treatment for fatty liver condition
Intercept Pharmaceuticals said Thursday that an extensive re-analysis of a large clinical trial involving its…
STAT+: Beyond a CRISPR treatment’s encouraging results, some scientists see a need for more data on risk
What happens when you CRISPR people? Few questions generated more contentious discussion in biotech in…
STAT+: FDA to convene second panel of outside experts to review Amylyx Pharma’s ALS treatment
Amylyx Pharmaceuticals said Tuesday that the Food and Drug Administration is bringing together a panel…
STAT+: Marijuana-induced high blunted by Anebulo Pharma pill, early study shows
Anebulo Pharmaceuticals said Tuesday that a single dose of its experimental pill blunted the effects…
STAT+: The biotech scorecard for the third quarter: 18 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third…
STAT+: ‘Really scared and frightened’: VC deals and valuations begin falling apart as biotech’s stock shock becomes one of the longest in history
The drug industry is experiencing one of the longest market downturns it has ever seen,…
STAT+: Not-so-happy midyear! Biotech CEOS, best and worst, and a hopeful sign of a turnaround
A few things on my mind: A very strange — and painful — year in…
STAT+: After abortion ruling, biotechs developing contraceptives say their work is more important — and fraught — than ever
SAN DIEGO — From San Diego to New Jersey, biotechs developing new forms of birth…
STAT+: A Celldex treatment induces symptom relief in patients with chronic hives
An experimental drug from Celldex Therapeutics induced complete symptom relief in half of patients with…